SHPH Shuttle Pharmaceuticals Inc Full Business Value

Brandmark of Shuttle Pharmaceuticals (SHPH)

Shuttle Pharmaceuticals (SHPH) is developing radiosensitizers to enhance radiation therapy, funding its research through investments. The stock's price history reflects an Enterprise Value of 24.94. Successful integration of the drug into global oncology protocols will ensure scalability with low distribution costs. Currently, the biotech firm is focusing on early-stage testing, relying exclusively on partnerships with scientific communities without mergers.

SHPH Shuttle Pharma: Enterprise Value in the range 11/23/2025 - 10/28/2026

SHPH (Shuttle Pharmaceuticals): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Performance Chart Shuttle Pharmaceuticals Holdings, Inc.|SHPH - Price Target Chart
- market capitalization data:
Market Valuation Shuttle Pharmaceuticals|SHPH - Enterprise Value
- book capitalization data:
Accounting Value of a Share Shuttle Pharmaceuticals|SHPH - Book Capitalization|Market Cap to Net Assets Ratio shuttlepharma.com|SHPH - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Shuttle Pharmaceuticals|SHPH - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio shuttlepharma.com|SHPH - Company Aggregate Debts|Debt to Book Value Shuttle Pharmaceuticals|SHPH - Company Long-Term Debts|Short-Term Debt Shuttle Pharmaceuticals
Fundamental company valuation:SHPH (Shuttle Pharmaceuticals Holdings, Inc.)
Manufactured products of Shuttle Pharmaceuticals Holdings, Inc.

This metric reflects operational efficiency through the sum of market capitalization and net debt, determining the actual cost of a full business buyout. For Shuttle Pharmaceuticals (SHPH), whose valuation depends on the success of brain cancer drug trials, the enterprise value serves as an indicator of the developer's financial stability during the intervals between clinical phases.

Direct competitors

CNS Pharmaceuticals Inc - Value Adjusted for Debt and Cash